Protocol

ESFT13: Therapeutic Trial for Newly Diagnosed Patients with Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Diseases

Solid Tumor : Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Description

This is a Phase II study for newly diagnosed Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Treatment will be based on the risk group outlined below.

Standard Risk

Standard risk includes participants with ESFT who are less than 14 years of age and have a localized, non-pelvic tumor. Previous clinical trials have shown that standard treatment is very effective for children who are less than 14 years of age, whose tumors are not in the pelvis and have not spread to other parts of the body. Therefore, Group A participants will receive standard treatment.

High Risk

High risk includes participants with ESFT who have metastatic disease or a primary pelvic tumor or are > 14 years of age or participants with DSRCT who have unresectable or abdominal/pelvic or metastatic disease. These patients are considered high risk because there is a greater chance of the tumor coming back with the standard treatments that are currently being used for ESFT or DSRCT.

High risk participants will receive the standard treatment in addition to the following:

Participants with abdominal or pelvic DSRCT may be eligible for hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of debulking surgery.


Objectives


Eligibility criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Contact

Fariba Navid, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.